Generic drug companies have been around for many years. Some people have estimated that the generic drug industry is growing at the rate of 10% every year.
Generic drugs continue to take a large market share and their expenses are much lower than the brand name companies. Generic drugs are much cheaper than innovator drugs and consumers prefer them because of their lower price.
The generic drug companies like to copy profitable innovative drugs once the patent expires.
The generic drug company chooses the trade name.
The company cannot change the generic name. Why? The generic name is already decided by the regulatory agency and all generic drugs using one reference drug must have the same generic name.
The generic name is the name of the active ingredient. The active ingredient must remain the same irrespective of the version of the drug you take.
In USA generic drug companies must submit an Abbreviated New Drug Application commonly referred to as ANDA.
The ANDA is sent to Center for Drug Evaluation and Research. In Canada generic drug companies submit their application to Therapeutic Products directorate.
The application is called abbreviated new drug submission (ANDS). Similar types of applications are usually submitted to many other regulatory agencies. The term “abbreviated” is used because generic companies submit only a short application for review. Generic drug companies are not required to carry out costly animal and clinical research.
The expensive research has already been carried out by the original brand company and there is no need to repeat it. Generic drug companies do not need to proof the safety of the medicinal ingredients.
They only need to proof that the generic drug is bio-equivalent to the innovator drug.
To get a generic drug approved by the FDA, Health Canada or the EU it drug must meet all the following conditions.
About 80 percent of all raw drug ingredients used to make brand and generic drugs in United States come from other countries.
It is very difficult to know where all the components of a generic drug or any other medicinal product whether it was manufactured in USA, Canada or any other country. We are living in a highly networked interdependent world.
Generic drug companies are allowed to make a generic drug which differs from the innovator drug in the following ways:
Different Shape: Many shapes are possible. The shapes depend on the type of tooling used
Different Color: The color is based on the addition of tiny amounts of approved coloring agents
Different Packaging: They may use different packaging material
Different Labeling: The labeling may not be significantly different. Only minor changes are allowed.
Different Flavoring: If there was a flavor in the brand generic drugs can have a different flavour
Different Preservative: If there were preservatives in the innovator the generic drugs may use different preservatives
Generic drugs are allowed to have different inactive ingredients. These ingredients are commonly referred to as excipients . They include substances that improve powder flow or compression to form better tablets. All the inactive agents must be considered to be safe by the regulatory agencies to be included in the generic drug.
Generic drugs may also have a different expiration date from the brand-name drug. However the generic drug must remain effective until its expiration date. This is also required for a brand-name product.
Both of these submissions are organized in modules as follows:
Module 1: This module contains administrative and prescribing information and other information depending on the region. It includes fully completed and signed forms
Module 2: This module consists of summaries and overviews of the other modules. This module has the following subsections
2.3 Qualities overall summary is a summary of the results or data reported in module 3
2.5 Clinical overview .This is an overview of the findings in the clinical study reports found in module 5
2.7 Clinical summaries. This consists of summaries of the bioequivalence studies found in the reports placed in module 5
Module 3: Quality consists of all the data relating to chemistry, manufacturing and controls.
Module 5: It consists of reports of clinical studies.
These are submitted by regulatory affairs personnel working for generic drug companies or consultants. In USA and Canada most applications are carried out using the eCTD format. Although an ANDS or ANDA is shorter than an innovative drug application, not everyone can submit a correct application.
There are many people out there who claim they can help you to submit an ANDA or an ANDS. They may know the process, but they may not understand the details required by the regulatory agencies.
They can cause you unnecessary delay. The problems they face are in the details.
As of December 2015 about 4,300 generic drugs were at different stages of review awaiting approval. The FDA placed the blame on the generic drug companies for submitting sloppy and deficient applications.
This is what slows down the review process. Sometimes applications lack vital information, such as relevant bioequivalence clinical research. Sometimes it’s not clear when the original drug will lose patent protection.
In some cases there are pending court cases over patent protection. Under these circumstances the generic drug will not be approved for marketing.
As many companies try to make generic drugs to cash on the growing need for generics, too many generic drug submissions demonstrate lack knowledge about pharmaceuticals or how to make them. FDA and other regulatory agencies such as Health Canada are not in the business of training sponsors on how to make pharmaceuticals. We may be able to help you.Please contact us.
Because generic drug companies duplicate many innovative drugs, they generally tend to employ many people. You are more likely to be employed by a generic company than an innovator drug company.
The following are some of the opportunities to check out:
Although some people may take more courses, we have the following courses that could help you to enhance your career in the generic drug companies or Brand name companies.
The following are some of the generic drug companies in Toronto. Apotex Inc. is the biggest in Canada.